National Development and Reform Commission, China’s anti-monopoly regulator, recently fined five local drug firms a total of nearly 4 million yuan for fixing the price of allopurinol, a treatment for gout and kidney disease, Reuters reported.
According to the NDRC, the drug firms colluded to increase the price of the allopurinol tablets from April 2014 to Sept. 2015.
“[The firms] created monopolies by agreeing to raise sales prices and artificially carve up the market,” the NDRC said in its official statement.
Allopurinol is on China’s essential drug list.
The NDRC emphasized that the involved firms have held several meetings where their officials negotiated to have a fixed price for the said tablet, hence violating the anti-monopoly law.
Full content: Yibada
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
FTC Throws the Bag: Tapestry’s Capri Deal Blocked Over Market Monopoly Concerns
Apr 22, 2024 by
CPI
Italy’s Antitrust Authority Investigates Enel’s Communication of Energy Price Hikes
Apr 22, 2024 by
CPI
UK Data Regulator Uncovers Flaws in Google’s Privacy Sandbox Proposal
Apr 22, 2024 by
CPI
Japan’s Antitrust Body Orders Google to Amend Ad Search Practices
Apr 22, 2024 by
CPI
Senator Blackburn Blasts Ticketmaster Amid DOJ Probe
Apr 22, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI